Filter Results:
(622)
Show Results For
- All HBS Web
(622)
- People (2)
- News (57)
- Research (449)
- Events (2)
- Multimedia (8)
- Faculty Publications (395)
Show Results For
- All HBS Web
(622)
- People (2)
- News (57)
- Research (449)
- Events (2)
- Multimedia (8)
- Faculty Publications (395)
- November 1985
- Case
Genetics Institute Enters the Seed Business
By: Ray A. Goldberg and Michael Joseph Kennedy
Goldberg, Ray A., and Michael Joseph Kennedy. "Genetics Institute Enters the Seed Business." Harvard Business School Case 586-077, November 1985.
- November 1978 (Revised February 1990)
- Case
Amicon Corp. (C)
Details the negotiations between Amicon and one potential licensee, Jackson. View Details
Keywords: Technology; Patents; Negotiation Process; Negotiation Participants; Health Care and Treatment; Biotechnology Industry
Capon, Noel. "Amicon Corp. (C)." Harvard Business School Case 579-095, November 1978. (Revised February 1990.)
- 06 Oct 2020
- Blog Post
2+2 Where Are They Now Spotlight: Curtis Wu (MBA 2018)
Can you describe your role?I currently work at Amgen Inc at their global HQ in Southern California. Amgen is the largest independent biotechnology company in the world by revenue and our top medicines include autoimmune drug Enbrel, white... View Details
- 01 Aug 2002
- News
For Alumni Only: Breakthrough Insights Program Debuts
case on the biotechnology firm Biogen, where a seemingly innocuous decision to license databases of new proteins discovered through genomic research wound up completely transforming the company's product-development process. As Vietor led... View Details
Keywords: Laura Singleton
- 01 Feb 1999
- News
Classmates Rally to Help Family Stricken with Rare Disease
scientists and researchers, in conjunction with several biotechnology companies, including Genzyme Corp., are now ready to test on humans an enzyme replacement therapy that has been successful in reversing the disease in laboratory... View Details
- 29 Jun 2022
- Blog Post
Harvard Business School Announces the 2022-2023 Blavatnik Fellows
led by Peter Barrett, PhD, faculty chair, and an advisory board of seasoned business and biotechnology leaders who serve as one-on-one mentors and provide strategic direction during the fellows' program year. “Since joining the Blavatnik... View Details
- 02 Aug 2004
- Research & Ideas
Health Care Research and Prospects
is a lot other work at the school going on around these issues by many other faculty. For instance, Dave Scharfstein is doing great work on how capital market forces influence the development strategies of biotechnology companies. David... View Details
- 07 Jul 2003
- Research & Ideas
The Organizational Model for Open Source
The more fundamental question that firms and policy makers need to be thinking about is just what type of good is software?—Siobhán O'Mahony Similar issues surface in the biotechnology world, where university and market conceptions of the... View Details
Keywords: by Mallory Stark
- 12 Oct 1999
- Research & Ideas
Porter’s Perspective: Competing in the Global Economy
therefore, become unique local centers of innovation for the likes of mutual funds, venture capital, and biotechnology in Greater Boston or aircraft equipment and design, boat and shipbuilding, and metal fabrication in Seattle. The list... View Details
Keywords: Re: Michael E. Porter
- Research Summary
Evolution of firm structure in vertical specialized technology supply chains
By: Willy C. Shih
The global market in many everyday products has been transformed by the internationalization of production. In many industries, semiconductors and electronic products in particular, a sequential mode of production has evolved in which goods are produced... View Details
- Research Summary
Industrial competitiveness in high tech and science-based businesses
By: Willy C. Shih
How do emerging economies develop industrial and technical capabilities that overtake those of advanced economies? Are there some industrial sectors that are especially susceptible to such targeting? What will it take to restore America’s... View Details
- September 2019
- Case
Bill & Melinda Gates Foundation: Shaping the Vaccine Manufacturing Ecosystem
By: Willy C. Shih
Vaccines for children has been a long-standing focus for the Bill & Melinda Gates Foundation, and its critical role in public health made its production an important economic and political issue. This case describes the Foundation's investment in a breakthrough vaccine... View Details
Keywords: Vaccine; Production; Supply Chain; Product; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Belgium
Shih, Willy C. "Bill & Melinda Gates Foundation: Shaping the Vaccine Manufacturing Ecosystem." Harvard Business School Case 620-021, September 2019.
- June 2010
- Teaching Note
Monsanto: Helping Farmers Feed the World (TN)
By: David E. Bell and Mary Louise Shelman
Teaching Note for [510025]. View Details
- March 2010 (Revised May 2012)
- Case
Myelin Repair Foundation: Accelerating Drug Discovery Through Collaboration
By: Karim R. Lakhani and Paul R. Carlile
This case presents the Myelin Repair Foundation's accelerated research collaboration model for drug discovery. It highlights the challenges of building a multi-disciplinary and multi-institutional research collaboration that is attempting to create a treatment for... View Details
Keywords: Research and Development; Intellectual Property; Risk and Uncertainty; Strategic Planning; Collaborative Innovation and Invention; Health Disorders; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry
Lakhani, Karim R., and Paul R. Carlile. "Myelin Repair Foundation: Accelerating Drug Discovery Through Collaboration." Harvard Business School Case 610-074, March 2010. (Revised May 2012.)
- April 2008
- Teaching Note
Viagen: Revolutioning the Livestock Industry (TN)
By: David E. Bell, Mary L. Shelman and Eliot Sherman
Teaching Note for [507021]. View Details
- March 2007
- Teaching Note
Monsanto: Realizing Biotech Value in Brazil (TN)
By: David E. Bell and Mary L. Shelman
- December 2006 (Revised January 2008)
- Case
ViaGen: Revolutionizing the Livestock Industry
By: David E. Bell, Reed Martin and Mary L. Shelman
ViaGen has invested heavily to develop cloning technology for the livestock industry. Cloning has the potential to significantly improve the genetics of livestock, leading to higher quality meat, healthier animals, and more efficient production. Since 2003, the firm... View Details
Keywords: Animal-Based Agribusiness; Business Plan; Governing Rules, Regulations, and Reforms; Marketing Communications; Industry Structures; Business and Government Relations; Genetics; Commercialization; Biotechnology Industry; Biotechnology Industry
Bell, David E., Reed Martin, and Mary L. Shelman. "ViaGen: Revolutionizing the Livestock Industry." Harvard Business School Case 507-021, December 2006. (Revised January 2008.)
- September 1990 (Revised November 1990)
- Case
DNAP: Looking to the Nineties
By: Ray A. Goldberg
Goldberg, Ray A. "DNAP: Looking to the Nineties." Harvard Business School Case 591-032, September 1990. (Revised November 1990.)
- November 2023 (Revised April 2024)
- Case
BiomX: Bringing Phage Back to the Stage
By: Paul A. Gompers, Elie Ofek, Orna Dan and Emilie Billaud
In the spring of 2023, and following the favorable results of a trial involving its phage cocktail for treating lung infections among cystic fibrosis (CF) patients, the leadership of BiomX had several critical issues to wrestle with. First, given its precarious... View Details
Keywords: Working Capital; Financing and Loans; Health Testing and Trials; Product Development; Research and Development; Science-Based Business; Commercialization; Biotechnology Industry; Biotechnology Industry
Gompers, Paul A., Elie Ofek, Orna Dan, and Emilie Billaud. "BiomX: Bringing Phage Back to the Stage." Harvard Business School Case 524-051, November 2023. (Revised April 2024.)
- September 2023 (Revised April 2024)
- Case
Atomwise: Strategic Opportunities in AI for Pharma
By: Satish Tadikonda
Abraham Heifets and his co-founder, Izhar Wallach, had founded Atomwise to develop i) an AI engine to transform drug discovery by creating better medicines faster, and ii) a machine learning-based discovery engine that combined the power of convolutional neural... View Details
Keywords: Business Model; Business Startups; AI and Machine Learning; Science-Based Business; Technological Innovation; Biotechnology Industry; Biotechnology Industry
Tadikonda, Satish. "Atomwise: Strategic Opportunities in AI for Pharma." Harvard Business School Case 824-043, September 2023. (Revised April 2024.)